Market closed
Bicara Therapeutics/$BCAX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
Website
BCAX Metrics
BasicAdvanced
$707M
-
-$18.09
-
-
Price and volume
Market cap
$707M
52-week high
$28.09
52-week low
$11.10
Average daily volume
340K
Financial strength
Current ratio
36.014
Quick ratio
35.961
Long term debt to equity
0.027
Total debt to equity
0.087
Management effectiveness
Valuation
Price to book
1.39
Price to tangible book (TTM)
1.39
Price to free cash flow (TTM)
-0.803
Growth
BCAX News
AllArticlesVideos
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewsWire·4 hours ago
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
GlobeNewsWire·2 weeks ago
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $707M as of February 25, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of February 25, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.